Male breast cancer is a rare disease. In Tunisia, it represents 1% of all breast cancers and 1.6% of Male neoplasia. This work is a retrospective study about 5 male patients with breast cancer, treated in the department of medical oncology at Fattouma Bourguiba University Hospital of Monastir (Tunisia) during a period of 3 years from March 2013 to March 2016. Results showed that: invasive ductual carcinoma was the histological type found in all cases; the Her 2 neu was not overexpressed in all cases; hormone receptors were positive in all patients. Two patients had a locally advanced disease. Two patients were diagnosed with metastatic disease; pulmonary and bone metastases. Three patients who were diagnosed with no metastatic disease have had a mastectomy with Axillary lymph node dissection. Adjuvant chemotherapy was administered in two patients. Loco regional radiotherapy was performed in three patients. Tamoxifen-based hormone therapy was administered in three patients. Two patients were treated with palliative chemotherapy. One patient received two lines of chemotherapy with a global survival of 16 months, while the other received only one line of palliative chemotherapy with a global survival of 2 months. One patient received palliative hormone therapy type Tamoxifen with progression free survival of 7 months. Three patients who received curative treatments are in remission of their disease. To conclude male breast cancer is a rare disease with multiple and varied risk factors. It is similar in its clinical, histological and prognostic characteristics to breast cancer in women but also has different characteristics.

Adenocarcinomas of intestinal type arising in mature cystic teratoma of ovary (MCT) are extremely rare and remain a diagnostic dilemma because of its similarities with MCT. Serum tumor markers CEA and SCC and also MRI may help in the preoperative diagnosis. Pathologist experience helps in intraoperative diagnosis.

As life expectancy is on the rise, it is predicted that a growing number of people will live beyond the age of 65 and therefore a higher number of elderly women will have breast diseases requiring significant health care and services. This study is aimed at investigating the characteristics, the treatment and outcomes of women older than 65 years old treated for breast diseases at our institution. This was a retrospective study covering the period from January 2003 to December 2011. It involved 92 patients aged over 65 and treated for breast disease in the Maternity Center of Monastir, Tunisia. The data included characteristics of patients and tumors, treatment and outcomes that were obtained through data extraction sheets. We reported a study of 92 women over the age of 65 of whom 77 women had malignant breast disease (83.6%) and 15 benign breast diseases (16.4%). Breast cancer was discovered at a mean age of 72.5 ± 6.6 years. Distant metastases were found in 5.3% of cases and infiltrative ductal carcinoma was detected in 85.7% of patients. Hormonal receptors were positive for estrogens in 64.7% of cases. Surgical treatment was performed in 73 patients and adjuvant treatment was prescribed for 67 women (86%). The complication rate was 16.6% among the 73 patients who underwent surgery. Benign breast diseases represented 16.3% of the mammary pathologies. Abscesses and fibrocystic mastopathy were the most frequent histological diagnoses. Despite great interest in geriatric gynecological pathology worldwide, many questions related to how optimally treat this patient population remain unanswered. In this study, a surgical treatment was performed in 94.8% of breast cancer patients and the complication rate was 16.6%.

Introduction: Burn-out is defined as a syndrome of emotional exhaustion, depersonalization and diminished self-achievement that affects individuals exposed to chronic occupational stress. Physicians and caregivers faced with the death of their patients, such as oncology, are particularly vulnerable to this syndrome. Objectives: To evaluate the burn-out of medical professionals in medical oncology, to research the predisposing factors and to analyze the functional complaints and the behavior of the staff associated with this syndrome. Methods: A descriptive and analytical cross-sectional study among medical oncology professionals practicing in public hospitals in the Tunisian territory who exercise more than two years in oncology; with the Maslach Burnout Inventory (MBI). Results: Our study population was predominantly female (81%). 53% are doctors and 47% are paramedical health care professionals. A high degree of emotional exhaustion, depersonalization and personal achievement were found in 63%, 53% and 59% in our population, respectively. With 21% global high burn-out. The female sex was associated with high emotional exhaustion and low personal accomplishment as well as global burn-out. This burn-out was attributed to factors associated with working conditions and professional climate, mainly: overwork, poor organization of service, lack of resources and time, lack of recognition, lack of communication, lack of respect, conflicts with colleagues, report unsatisfactory salary effort and aggressions by patients and their families. Functional complaints and health care professional’s behavior associated with burn-out were: feelings of sadness, blockage, and irritability, sleep disorders, unexplained pain, epigastralgia, addictive behaviors, psychotropic consumption, suicidal thoughts, decreased performance and desire for a job transfer. Conclusions: By its impact on professionals, burn-out in medical oncology represents a major threat to the quality of health care. Its etiologies, although complex and intricate, are well known. Its prevention and its support are possible, but involve mobilization at all levels.

In Tunisia, bladder cancer represents the first urological cancer before even prostate cancer. However, its diagnosis is often delayed to the stage of invasive tumor. Systemic chemotherapy represents an option for inoperable and/or metastatic forms. Our study's aims were to report our center's therapeutic results for locally advanced and metastatic forms of bladder cancer and to analyze its prognosis factors. In our 40 patients with bladder cancer advanced stages (locally advanced and metastatic), transitional cell carcinoma was the most common histological type (82.5%); mean age at diagnosis was 63.3 ± 10.5 years with a sex ratio equal to 12.3; radical cystectomy and radiation therapy were performed separately both in 35% of cases and chemotherapy in 60%; cisplatin associated with gemcitabine was the most used regimen and navelbine monotherapy was used as second-line chemotherapy; median overall survival was 14.4 months, and its influencing factors according to our results were: ECOG score, T and M tumor stages, primary tumor surgery and adjuvant chemotherapy.